Skip to content

Efficacy and safety of SGLT2 inhibitors in patients with acute coronary syndrome: a prospective, single-center, randomized controlled study

Efficacy and safety of SGLT2 inhibitors in patients with acute coronary syndrome: a prospective, single-center, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100060
Enrollment
Unknown
Registered
2025-04-02
Start date
2025-04-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

SGLT2 inhibitor group:SGLT2 inhibitors
Control group:Usual care

Sponsors

Xi'an Jiaotong University Second Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The age of the patients ranged from 18 to 80 years; 2.Patients diagnosed with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction who underwent coronary intervention (including stent or drug-balloon implantation) within 72 hours; 3.The informed consent to participate in this clinical trial was signed.

Exclusion criteria

Exclusion criteria: 1.Diabetes; 2.The patient had a history of chronic heart failure or had a left ventricular ejection fraction <= 40% before admission; 3.cardiogenic shock; 4.Renal insufficiency (glomerular filtration rate < 30 mL/min/1.73 m^2); 5.Hypoglycemia, acidosis, hepatic insufficiency; 6.Previous or planned coronary-artery bypass grafting; 7.They were currently receiving an SGLT2 inhibitor or had received an SGLT2 inhibitor within 4 weeks before enrollment; 8.Pregnancy, lactation, a history of cancer within the previous 3 years, autoinflammatory conditions, current or planned long-term treatment with systemic glucocorticoids, acute symptomatic urinary tract infection or genital infection, or clinically significant nontransient hematologic disorders; 9.Patients with contraindications to SGLT2 inhibitors;

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular and cerebrovascular events (the sum of events of myocardial infarction, heart failure, stroke, all-cause death, cardiovascular death, hospitalization for heart failure, and all-cause hospitalization);

Secondary

MeasureTime frame
Cardiac structural and functional indicators (including pro-brain natriuretic peptide, left ventricular end-diastolic diameter, left ventricular ejection fraction, etc.);4 w, 12 w, 6 months and 12 months;

Countries

China

Contacts

Public ContactChen Guo

Xi'an Jiaotong University Second Affiliated Hospital

guochenlzu@126.com+86 15691923121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026